Atavistik: Identifying allosteric modulators of metabolic proteins
Emerging Company Profile: Utah spinout launching with $60M to identify allosteric regulatory sites on metabolic targets
Launching with a $60 million series A round, Atavistik is advancing an allosteric modulator discovery platform built on technology developed by Jared Rutter at the University of Utah.
Rutter’s presentation at a meeting spurred The Column Group’s John Josey and Tim Kutzkey to learn more about the scientist’s high-throughput allosteric site discovery platform. The firm ultimately spun the technology out into Atavistik Bio Inc. with a focus on metabolic enzymes, and led the company’s A round...